CARA

Cara Therapeutics

18.09 0.01 (0.06%)

Delayed Prices By NASDAQ, in USD Market Closed

Trade

18.08

18.14

Overview

Prev Close18.09

Day's Range16.65 - 18.09

52 Week Range8.87 - 22.55

Average Volume (3m)506.8K

1-Year Return30.45%

Beta1.2128

Market Cap902.27M

P/E Ratio223.61

Revenue135.08M

EPS0.0809

Dividend (Yield)0 (0%)

1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max

Chart times in UTC

Sector
Health Technology

Industry Biotechnology

CEO Derek T. Chalmers, PhD

Employees 80

FINANCIAL SUMMARY

For the quarter ended 30/9/2020, Cara Therapeutics 's revenues increased by 64.47% and amounted to 9.27M. Net income increased by 34.14% to -16.51M. Net assets decreased by 9.28% to 127.85M and EPS increased from -0.54 to -0.35.

CARA's Investor Relations

Income StatementBalance SheetCash Flow Statement

Quarterly

N/A

-14,812.64%

3.99%

-57.59%

12/19

03/20

06/20

09/20

4.51M

8.09M

5.63M

9.27M

N/A

-29.97M

-30M

-25.88M

-17.02M

-28.61M

-28.92M

-25.07M

-16.51M